Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Ranging Study of Modafinil for Methamphetamine Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00630097
Recruitment Status : Unknown
Verified June 2010 by California Pacific Medical Center Research Institute.
Recruitment status was:  Active, not recruiting
First Posted : March 6, 2008
Last Update Posted : June 22, 2011
Sponsor:
Information provided by:
California Pacific Medical Center Research Institute

Brief Summary:
Patients treated for methamphetamine dependence have high rates of relapse, and no pharmacotherapy has yet been demonstrated to be efficacious. Modafinil (d, l-2-[(diphenylmethyl)sulfinyl]acetamide) is a novel wake- and vigilance-promoting agent that is chemically and pharmacologically dissimilar to CNS stimulants. It is well tolerated and has low abuse liability compared to CNS stimulants. Modafinil is FDA approved for a variety of sleep disorders, may relieve methamphetamine withdrawal symptoms, improves cognitive function, has been shown to reduce cocaine use in dependent users, and is safe when coadministered with intravenous methamphetamine. We will conduct a randomized dose ranging clinical trial of modafinil to establish its safety and efficacy as a pharmacotherapy for methamphetamine dependence.

Condition or disease Intervention/treatment Phase
Substance Dependence Amphetamine Dependence Drug: modafinil Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Dose Ranging Study of Modafinil for Methamphetamine Dependence
Study Start Date : December 2009
Estimated Primary Completion Date : June 2011
Estimated Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine


Intervention Details:
  • Drug: modafinil
    Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.


Primary Outcome Measures :
  1. Methamphetamine-negative urine samples will be analyzed using a generalized estimating equation model [ Time Frame: end of study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age between 18 and 50 years
  2. Patient is agreeable to conditions of study and signs consent form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630097


Locations
Layout table for location information
United States, California
CPMC
San Francisco, California, United States, 94110
Sponsors and Collaborators
California Pacific Medical Center Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Gantt Galloway, PharmD California Pacific Medical Center

Layout table for additonal information
Responsible Party: Gantt Galloway, California Pacific Medical Center Research Institute
ClinicalTrials.gov Identifier: NCT00630097    
Other Study ID Numbers: 27.140
First Posted: March 6, 2008    Key Record Dates
Last Update Posted: June 22, 2011
Last Verified: June 2010
Keywords provided by California Pacific Medical Center Research Institute:
methamphetamine addiction, meth dependence
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Amphetamine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Modafinil
Central Nervous System Stimulants
Physiological Effects of Drugs
Wakefulness-Promoting Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action